The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of patient enrollment as planned. There has been no safety concern with the use of leuprolide (FP-001) injectable Emulsion in pediatric CPP patients. TAIPEI, Feb. 17, 2025 /PRNewswire/ -- Foresee...
Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals Receives the Third Positive Recommendation from the DSMB to Continue the Casppian Study )
Also on site :
- 80s Metal Icons Play Epic First UK Show in 6 Years Ahead of Black Sabbath Opener
- Mel Owens' Ex-Wife Issues Bold Statement on His Upcoming 'Golden Bachelor' Season: 'It's Going to be Bad'
- European retailer inspired by ‘new Med’ hits major milestone opening its 50th store in the US – and 15 more are coming